Importing Pharmaceuticals into the United States: A Practical Guide
The United States is the largest pharmaceutical market in the world, and its imports are screened at the border by the FDA working alongside Customs and Border Protection. A drug entry is filed electronically and reviewed against FDA data before the goods are allowed to proceed, and investigational product moves under an IND rather than a marketing approval. This guide covers who regulates US pharmaceutical imports, what a commercial versus investigational import needs, the controlled-substance overlay, and where entries get held.
Who regulates pharmaceutical imports into the United States
Drugs imported into the US are regulated by the Food and Drug Administration (FDA), with entries filed through Customs and Border Protection (CBP). When a shipment arrives, the entry is transmitted electronically through the Automated Commercial Environment, and the FDA screens it, historically through its PREDICT risk system, to decide whether it may proceed, needs examination, or is detained. Controlled substances add a second regulator, the Drug Enforcement Administration (DEA).
What a commercial import needs
For a commercial drug import, the baseline expectations are:
- A legally importable product. The drug is FDA-approved, or otherwise permitted to enter, and foreign establishments are registered with the FDA and their drugs listed where required.
- An importer or consignee of record, with a customs bond and a licensed customs broker in most cases.
- An FDA entry filing through ACE, with the correct product codes and affirmations of compliance.
- DSCSA data for products moving into the US commercial supply chain, which is serialised under the Drug Supply Chain Security Act.
| Document | Purpose |
|---|---|
| Commercial invoice and packing list | Customs valuation and description. |
| FDA entry with product codes | Identifies the article to the FDA for review. |
| Affirmations of compliance | Declare registration, listing and approval status. |
| IND reference (investigational) | Authorises import of an investigational drug. |
| DEA import permit (controlled) | Required for controlled substances. |
| Temperature record | Cold-chain evidence for temperature-sensitive products. |
Investigational drugs and clinical trial material
An investigational drug is imported under an Investigational New Drug application (IND). The entry should reference the IND, and the material is for use in the authorised study rather than for sale. Sponsors typically use an importer of record and a customs broker familiar with FDA entries, and the FDA expects the investigational status to be clear on the paperwork. Because a mismatch between the declared status and the entry is a common cause of detention, accountability from import through site delivery matters.
Controlled substances and special categories
- Controlled substances. Import requires DEA registration and an import permit, for example a DEA import permit for Schedule I and II substances, in addition to FDA requirements.
- Cold chain. Continuous temperature data and a documented excursion response are expected.
- Dangerous goods. Dry ice and certain biologicals require the correct transport declaration.
Where entries get held up
- 1The declared product status does not match FDA registration, listing or approval, so the entry is detained.
- 2An investigational drug entry does not clearly reference a valid IND.
- 3Controlled-substance paperwork or the DEA import permit is missing.
- 4Temperature data has a gap, forcing a quality decision.
- 5Entry data filed through ACE is incomplete or inconsistent with the physical goods.
Frequently asked questions
Commercial drugs generally must be FDA-approved or otherwise legally importable, with foreign establishments registered and their drugs listed. Each entry is filed through the Automated Commercial Environment and screened by the FDA, which decides whether it may proceed, needs examination, or is detained.